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cator molecule must not impair the binding affinity of the
protein to a great extent to provide a higher sensitivity. A
modified ~-lactamases with a residue on the Q-loop or
outside the Q-loop but close to the active site of ~-lactamase
being replaced by a reactive residue is developed in this
invention.
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BRIEF DESCRIPTION OF THE DRAWINGS
10
A second aspect of this invention provides a method for
detecting ~-Iactam antibiotics or ~-Iactamase inhibitors in a
sample, including the steps of:
exposing the sample to a ~-Iactamase with a non-reactive
residue on the Q-Ioop replaced by a reactive residue,
for binding said ~-Iactamase with said ~-Iactam anti-
biotics or ~-Iactamase inhibitors;
detecting a signal emitted by the ~-Iactamase bound with
said ~-Iactam antibiotics or ~-Iactamase inhibitors.
Preferably, the method of this invention further includes
the step of comparing the signal emitted by the ~-Iactamase
bound with said ~-Iactam antibiotics or ~-Iactamase inhibi-
tors, with a signal emitted by the ~-Iactamase from a control
sample having no ~-Iactam antibiotics and ~-Iactamase
15 inhibitors.
Yet another aspect of this invention provides an apparatus
for detecting ~-Iactam antibiotics or ~-Iactamase inhibitors
in a sample incorporating a ~-Iactamase with a non-reactive
residue on the Q-Ioop replaced by a reactive residue.
Preferred embodiments of the present invention will now
be explained by way of example and with reference to the
accompany drawings in which:
FIG. 1 shows the tertiary structure of ~-Iactamase I;
FIG. 2 shows the ESI mass spectrum of (A) E166C and
(B) E166Cf mutants;
FIG. 3 shows the CD spectra of the wild-type ~-Iactamase
I, E166ct and E166Cf mutants at the same concentration
(6.0xlO M) in 50 mM phosphate buffer (pH 7.0);
FIG. 4 shows the Fluorescence spectra of the E166Cf
enzyme (1.2xlO-7 M) in 50 mM phosphate buffer (pH 7.0)
in the presence of 1.0xlO-4 M penicillin G (a), 1.0xlO-5 M
penicillin G (b), 1.0xlO-6 M penicillin G (c), 1.0xlO-7 M
penicillin G (d), 1.0xlO-8 M penicillin G (e) and 0 M
penicillin G (t). The E166Cf enzymes were incubated with
various concentrations of penicillin G for 130 s at room
temperature before measurement. Excitation wavelength:
40 494 nm;
FIG. 5 shows the Time-resolved fluorescence measure-
ments of the E166Cfenzyme (1.2xlO-7 M) at 515 nm in 50
mM phosphate buffer (pH 7.0) in the presence of 1.0xlO-4
M penicillin G (a), 1.0xlO-5 M penicillin G (b), 1.0xlO-6 M
45 penicillin G (c), 1.0xlO-7 M penicillin G (d) and 1.0xlO-8
M penicillin G (e). Excitation wavelength: 494 nm. The inset
shows the plot of the change in fluorescence intensity (at the
peak maxima) versus log (penicillin G, M);
FIG. 6 shows the time-resolved fluorescence measure-
50 ments of the E166Cfenzyme (1.2xlO-7 M) at 515 nm in 50
mM phosphate buffer (pH 7.0) in the presence of 1.0xlO-4
M penicillin V (a), 1.0xlO-5 M penicillin V (b), 1.0xlO-6 M
penicillin V (c), 1.0xlO-7 M penicillin V (d) and 1.0xlO-8 M
penicillin V (e). Excitation wavelength: 494 nm. The inset
55 shows the plot of the change in fluorescence intensity (at the
peak maxima) versus log (penicillin V, M);
FIG. 7 shows the time-resolved fluorescence measure-
ments of the E166Cfenzyme (1.2xlO-7 M) at 515 nm in 50
mM phosphate buffer (pH 7.0) in the presence of 1.0xlO-4
60 M ampicillin (a), 1.0xlO-5 M ampicillin (b), 1.0xlO-6 M
ampicillin (c), 1.0xlO-7 M ampicillin (d) and 1.0xlO-8 M
ampicillin (e). Excitation wavelength: 494 nm. The inset
shows the plot of the change in fluorescence intensity (at the
peak maxima) versus log (ampicillin, M);
FIG. 8 shows the time-resolved fluorescence measure-
ments of the E166Cfenzyme (1.2xlO-7 M) at 515 nm in 50
mM phosphate buffer (pH 7.0) in the presence of 1.0xlO-4
FIELD OF THE INVENTION
OBJECTS OF THE INVENTION
SUMMARY OF THE INVENTION
BACKGROUND OF THE INVENTION
1
MODIFIED ~-LACTAMASESAND USES
THEREOF
~-Lactam antibiotics (e.g. penicillins and cephalosporins)
are an important class of antibacterial agents widely used in
clinical therapies and as health promoting agents in animal
feedstuffs. The clinical function of ~-Iactam antibiotics
relies on their inhibitory effect on the activity of penicillin-
binding proteins which are responsible for synthesizing
bacterial cell wall. However, the clinical importance of
~-Iactam antibiotics has been challenged by the emergence 20
of ~-Iactamaseswhich are capable of inactivating ~-Iactam
antibiotics by hydrolyzing the ~-Iactam ring to carboxylic
acid. To respond to this clinical problem, the pharmaceutical
industry has produced a wide range of ~-Iactam antibiotics
(which have stronger resistance toward the hydrolyzing 25
action of ~-Iactamases) and new ~-Iactamase inhibitors
(which can irreversibly block the enzyme's active site via
covalent modification). In order to search for a potent
antibiotic from a large pool of drug candidates rapidly, a
convenient tool that can screen bacteria for ~-Iactamases 30
against a panel ofvarious antibiotics is desirable. Moreover,
a sensing tool that can detect ~-Iactamase inhibitors and
~-Iactam antibiotics can also be useful. Such a tool can be
used in the discovery of ~-Iactam antibiotics and new
~-Iactamase inhibitors, and utilized in routine measurement 35
of antibiotic residues in liquid and food samples (e.g. milk).
This invention relates to modified ~-Iactamases that can
be used in the detection of ~-Iactam antibiotics and ~-Iac­
tamase inhibitors, and/or in screening bacteria for ~-Iacta­
mases against a panel of ~-Iactam antibiotics.
Therefore, it is an object of this invention to resolve at
least one or more of the problems as set forth in the prior art.
As a minimum, it is an object ofthis invention to provide the
public with a useful choice.
Accordingly, this invention provides ~-Iactamases with a
non-reactive residue replaced by a reactive residue.
Preferably the reactive residue is selected from the group
consisting of amino acids containing a free alcohol group,
amino acids containing a free carboxylic acid group, or
amino acids containing a free amine group. More preferably,
the reactive residue is cysteine.
Preferably, the non-reactive residue is on the Q-Ioop of
said ~-Iactamase.
Preferably, the reactive residue is further reacted with an
indicator molecule to generate a signal to detect ~-Iactam
antibiotics or ~-Iactamase inhibitors. More preferably, the
indicator molecule is a fluorophore.
Optionally, the non-reactive residue is Glu-166 residue.
Preferably, the ~-Iactamase is a mutant. More preferably,
the ~-Iactamase is a singly mutated mutant. Alternatively,
the ~-Iactamase is a multiply mutated mutant. For example, 65
in one specific embodiment, the ~-Iactamase is a E166C
mutant.
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DETAILED DESCRIPTION OF THE
PREFERRED EMBODIMENT
This invention is now described by way of example with
reference to the figures in the following paragraphs.
Objects, features, and aspects of the present invention are
disclosed in or are obvious from the following description.
It is to be understood by one of ordinary skill in the art that
the present discussion is a description of exemplary embodi-
ments only, and is not intended as limiting the broader
aspects of the present invention, which broader aspects are
embodied in the exemplary constructions.
One way to satisfY the objects mentioned above is to
develop a biosensor by incorporating a reporter group or
indicator molecule (e.g. luminescent probes) into a biomol-
ecule (e.g. ~-lactamase or any penicillin binding proteins)
such that the reporter group can transform the substrate or
inhibitor-binding event into a measurable signal. This can be
FIG. 21 shows the time-resolved fluorescence measure-
ments of the E166Cf enzyme (1.2x1O-7 M) at 520 nm in
untreated milk in the presence of 1.0x1O-4 M penicillin G
(a), 1.0x1O-5 M penicillin G (b), 1.0x1O-6 M penicillin G
5 (c), 1.0x1O-7 M penicillin G (d) and in the absence of
penicillin G (e). Excitation wavelength: 485 nm. The inset
shows the plot of the change in fluorescence intensity (at the
peak maxima) versus log (penicillin G, M);
FIG. 22 shows the time-resolved fluorescence measure-
ments of the E166Cf enzyme (1.2x1O-7 M) at 520 nm in
untreated milk in the presence of 1.0x1O-4 M ampicillin (a),
1.0x1O-5 M ampicillin (b), 1.0x1O-6 M ampicillin (c), 1.0x
10-7 M ampicillin (d) and in the absence of ampicillin (e).
Excitation wavelength: 485 nm. The inset shows the plot of
the change in fluorescence intensity (at the peak maxima)
versus log (ampicillin, M);
FIG. 23 shows the time-resolved fluorescence measure-
ments of the El 66Cf enzyme (1.2x1O-7 M) in 50 mM
phosphate buffer (pH 7.0) with (A) penicillin G (1.0x1O-4
M), (B) penicillin V (1.0x1O-4 M), (C) ampicillin (1.0x1O-4
M), (D) cefuroxime (1.0x1O-4 M), (E) cefoxitin (1.0x1O-4
M) and (F) moxalactam (1.0x1O-4 M) as substrates in the
absence of ~-lactamase II (a) and in the presence of ~-lac­
tamase II (b). Excitation wavelength: 485 nm;
FIG. 24 shows the time-resolved fluorescence measure-
ments of the E166Cf enzyme (1.2x1O-7 M) in 50 mM
phosphate buffer (pH 7.0) with (A) penicillin G (1.0x1O-4
M), (B) penicillin V (1.0x1O-4 M), (C) ampicillin (1.0x1O-4
M), (D) cefuroxime (1.0x1O-4 M), (E) cefoxitin (1.0x1O-4
M) and (F) moxalactam (1.0x1O-4 M) as substrates in the
absence of penPC ~-lactamase (a) and in the presence of
penPC ~-lactamase (b). Excitation wavelength: 485 nm;
FIG. 25 shows the time-resolved fluorescence measure-
ments of the E166Cf enzyme (1.2x1O-7 M) in 50 mM
phosphate buffer (pH 7.0) with (A) penicillin G (1.0x1O-4
M), (B) penicillin V (1.0x1O-4 M), (C) ampicillin (1.0x1O-4
M), (D) cefuroxime (1.0x1O-4 M), (E) cefoxitin (1.0x1O-4
M) and (F) moxalactam (1.0x1O-4 M) as substrates in the
absence ofpenP ~-lactamase (a) and in the presence of penP
~-lactamase (b). Excitation wavelength: 485 nm; and
FIG. 26 shows the time-resolved fluorescence measure-
ments of the E166Cf enzyme (1.2x1O-7 M) in 50 mM
phosphate buffer (pH 7.0) with (A) penicillin G (1.0x1O-4
M), (B) penicillin V (1.0x1O-4 M), (C) ampicillin (1.0x1O-4
M), (D) cefuroxime (1.0x1O-4 M), (E) cefoxitin (1.0x1O-4
M) and (F) moxalactam (1.0x1O-4 M) as substrates in the
absence of TEM-l ~-lactamase (a) and in the presence of
TEM-1 ~-lactamase (b). Excitation wavelength: 485 nm.
55
3
M cefuroxime (a), 1.0x1O-5 M cefuroxime (b), 1.0x1O-6 M
cefuroxime (c), 1.0x1O-7 M cefuroxime (d) and 1.0x1O-8 M
cefuroxime (e). Excitation wavelength: 494 nm. The inset
shows the plot of the change in fluorescence intensity (at the
peak maxima) versus log (cefuroxime, M);
FIG. 9 shows the time-resolved fluorescence measure-
ments of the E166Cf enzyme (1.2x1O-7 M) at 515 nm in 50
mM phosphate buffer (pH 7.0) in the presence of 1.0x1O-4
M cefoxitin (a), 1.0x1O-5 M cefoxitin (b), 1.0x1O-6 M
cefoxitin (c) and 1.0x1O-7 M cefoxitin (d). Excitation wave- 10
length: 494 nm. The inset shows the plot of the change in
fluorescence intensity (at the peak maxima) versus log
(cefoxitin, M);
FIG. 10 shows the time-resolved fluorescence measure-
ments of the E166Cf enzyme (1.2x1O-7 M) at 515 nm in 50 15
mM phosphate buffer (pH 7.0) in the presence of 1.0x1O-4
M moxalactam (a), 1.0x1O-5 M moxalactam (b), 1.0x10-6M
moxalactam (c), 1.0x1O-7 M moxalactam (d) and 1.0x1O-8
M moxalactam (e). Excitation wavelength: 494 nm. The
inset shows the plot of the change in fluorescence intensity 20
(at the peak maxima) versus log (moxalactam, M);
FIG. 11 shows the time-resolved fluorescence measure-
ments offree fluorescein (1.2x1O-7 M) at 512 nm in 50 mM
phosphate buffer (pH 7.0) in the presence of unlabeled
E166C enzyme (1.2x1O-7 M) with (A) 1.0x1O-5 M penicil- 25
lin G, (B) 1.0x1O-5 M penicillin V, (C) 1.0x1O-5 M ampi-
cillin, (D) 1.0x1O-5 M cefuroxime, (E) 1.0x1O-5 M cefoxitin
and (F) 1.0x1O-5 M moxalactam as substrates. Excitation
wavelength: 494 nm;
FIG. 12 shows the time-resolved fluorescence measure- 30
ments of the E166Cf enzyme (1.2x1O-7 M) at 515 nm in 50
mM phosphate buffer (pH 7.0) in the presence of 1.0x1O-6
M penicillin G (a) and 1.0x1O-7 M penicillin G (b). Exci-
tation wavelength: 494 nm;
FIG. 13 shows the time-resolved fluorescence measure- 35
ments of the E166Cf enzyme (1.2x1O-7 M) at 515 nm in 50
mM phosphate buffer (pH 7.0) in the presence of 1.0x1O-4
M penicillin G (a) and 1.0x1O-5 M penicillin G (b). Exci-
tation wavelength: 494 nm;
FIG. 14 shows the time-resolved fluorescence measure- 40
ments of the E166Cf enzyme (1.2x1O-7 M) at 515 nm in 50
mM phosphate buffer (pH 7.0) in the presence of 1.0x1O-4
M cefoxitin (a) and 1.0x1O-6 M cefoxitin (b). Excitation
wavelength: 494 nm;
FIG. 15 shows the circular dichroism signals (258 nm) of 45
cefuroxime in 50 mM phosphate buffer (pH 7.0) as a
function of time in the presence of E166Cf enzyme (l.2x
10-7 M);
FIG. 16 shows the circular dichroism signals (264 nm) of
cefoxitin in 50 mM phosphate buffer (pH 7.0) as a function 50
of time in the presence of E166Cf enzyme (1.2x1O-7 M);
FIG. 17 shows the circular dichroism signals (265 nm) of
moxalactam in 50 mM phosphate buffer (pH 7.0) as a
function of time in the presence of E166Cf enzyme (l.2x
10-7 M);
FIG. 18 shows the time-resolved fluorescence measure-
ments of the E166Cf enzyme (1.2x1O-7 M) at 515 nm in 50
mM phosphate buffer (pH 7.0) with 1.0x1O-4 M sulbactam
as substrate. Excitation wavelength: 494 nm;
FIG. 19 shows the time-resolved fluorescence measure- 60
ments of the E166Cf enzyme (1.2x1O-7 M) at 515 nm in 50
mM phosphate buffer (pH 7.0) with 1.0x1O-3 M clavulanate
as substrate. Excitation wavelength: 494 nm;
FIG. 20 shows the (A) A 96-well microtiter plate (Coming
Costar) and (B) the schematic diagram of the set-up used in 65
the detection of ~-lactam antibiotics in milk and in drug
screening experiments;
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achieved by incorporating a reactive residue, for example
thiol-containing cysteine, into a protein by site-directed
mutagenesis, and then labeling the cysteine residue with an
indicator molecule, for example a thiol-reactive reporter
group. Such biosensors offer a number of advantages,
including high sensitivity, high specificity, simplicity and
low cost. However, this approach requires that the attached
indicator molecule must not impair the binding affinity ofthe
protein to a great extent to provide a higher sensitivity.
The structure and amino acid sequence of ~-Iactamasecan
be found in the following References I to 5, respectively:
1. Madgwick, P. J. and Waley, S. G. ~-Iactamase I from
Bacillus cereus. Structure and site-directed mutagenesis
(1987) Biochem. J. 248, 657-662.
2. Aschaffenburg, R., Phillips, D. C, Sutton, B. J., Baldwin,
G., Kiener, P. A., Waley, S. G. Preliminary crystallo-
graphic data for ~-Iactamase I from Bacillus cereus 569.
(1978) J. Mol. Bioi. 120,447-449.
3. Samraoui, B., Sutton, B. J., Todd, R. J., Artymiuk, P. J.,
Waley, S. G., Phillips, D. C. Tertiary structural similarity
between a class A ~-Iactamase and a penicillin-sensitive
D-anlanyl carboxypeptidase-transpeptidase. (1986)
Nature 320, 378-380.
4. Moews, P. c., Knox, J. R., Dideberg, 0., Charlier, P.,
Frere, J. M., ~-Iactamase Bacillus licheniformis 7491C at
2 A resolution. (1990) Proteins 7, 156-171.
5. Ambler, R. P.; Coulson, A. F. W, Frere, J.-M.; Ghuysen,
J.-M.; Joris, B.; Forsman, M.; Levesque, R. c.; Tiraby, G.;
Waley, S. G. A standard numbering scheme for the Class
A ~-Iactamase, (1991), Biochem. J. 276, 269-272.
In this invention, a biosensor for ~-Iactam antibiotics and
~-Iactamase inhibitors is provided by attaching an indicator
molecule close to the active site of a ~-Iactamase. In a
specific embodiment of this invention, the indicator mol-
ecule is an environmentally sensitive fluorescein molecule,
and the ~-Iactamase is a mutant. The mutant (EI66C) was
constructed in which a residue on the Q-Ioop of the wild-
type ~-Iactamase I was replaced by a reactive residue by
site-directed mutagenesis. The reactive residue can be any
residue having a free function group to react with an
indicator molecule. For example, amino acids containing a
free alcohol group such as serine, threonine and tyrosine
may be used. These amino acids can be derivatised with
salicylaldehyde, which can then be coupled to fluorescent
reagents such as 1,2-diamino-4,5-dimethoxybenzene.
Amino acids containing a free carboxylic acid group such as
glutamic acid and aspartic acid may also be used, which can
be coupled to carbodiimides which then react with a fluo-
rescent reagent, or to carbodiimides which contain a fluo-
rophore. A further option is to use amino acids containing a
free amine group such as lysine, which can be coupled to
isothiocyanantes or succinimidyl esters.
In one specific embodiment, the replaced residue is the
Glu-166 residue (according to the ABL number system,
Reference 5), and the reactive residue is a cysteine residue.
The mutant was then labeled with an indicator molecule, in
one specific embodiment a thiol-reactive fluorescein-5-ma-
leimide, at its reactive residue, the cysteine residue, to fonn
E166Cf, a specific modified ~-Iactamase of this invention.
It should be emphasized that this invention shall not be
limited by the EI66Cf constructed. The reside to be replaced
on the Q-Ioop of the wild-type ~-Iactamasecan be at various
positions including Asn163, Arg164, Phe165, Glu166,
Thr167, Glu168, Leu169, Asn170, Glu171, Alal72, Ile173,
Pro174, Gly175, Asp176, Ilel77, Arg178, though preferably
to be the Glu-166 residue. Further, residues outside the
Q-Ioop but close to the active site can also be used, e.g.
6
Ser70, Lys73, Asp104, Serl30, and Lys234. The ~-Iacta­
mase can be wild type ~-Iactamaseor its mutant, whether it
is a singly or multiply mutated mutant, in which a single
mutated mutant contains only one amino acid substitution
while a multiply mutated mutant contains more than one
amino acid substitutions. Further, the indicator molecule can
be any other molecule capable of emitting a detectable
signal other than fluorescent signal. However, fluorophore
capable of emitting fluorescent signal as fluorescent signal
10 may create less influence to the structure of the enzyme.
Referring to the specific E166Cf, as the wild-type ~-Iac­
tamase I has no cysteine, incorporation of a cysteine residue
into the protein allows the fluorophore to be specifically
attached at the desired site. The Glu-166 residue was chosen
15 as the labeling site not only because of its closeness to the
enzyme's active site, but also the flexibility of the Q-Ioop
which allows the attached fluorescein molecule to move
when a substrate enters the active site. Thus, the EI66Cf
mutant can serve as a reagentless tool to detect ~-Iactam
20 antibiotics with high sensitivity and specificity. Moreover,
substrate competition between the labeled enzyme (EI66Cf)
and bacterial ~-Iactamasewill lead to a change in antibiotic
concentration (e.g. decrease in antibiotic concentration due
to the hydrolytic action of bacterial ~-Iactamase) and hence
25 generating different fluorescence signals, thus allowing the
labeled enzyme to be used conveniently in drug screening,
selecting the most appropriate ~-Iactam antibiotic for
patients with bacterial infection.
The synthesis ofEI66Cf and its use in detecting ~-Iactam
30 antibiotics and ~-Iactamase inhibitors, and/or in screening
bacteria for ~-Iactamases against a panel of ~-Iactam anti-
biotics will now be described in details. However, as there
are various options in designing the modified ~-Iactamase as
mentioned above, suitable modifications may be necessary
35 to the below methods, which are readily available to a
person skilled in the art.
Expression and purification of wild-type ~-Iactamase I
and EI66C mutant were perfonned as described previously
(Reference 6: Leung, Y. C. Robinson, C. v., Alpin, R. T.,
40 Waley, S. G., Site-directed synthesis of~-Iactamase I: role of
Glu-166 (1994) Biochem. J. 299, 671-678). with slight
modifications. Both wild-type ~-Iactamase I and EI66C
mutant were expressed in B. subtilis IA304 (<jJ105MU331).
A bacterial strain was streaked on an agar plate containing
45 5 flglml chloramphenicol, and the plate was incubated at 37°
C. for 24 h. A single bacterial colony from the agar plate was
inoculated into 100 ml of sterilized BHY medium (37 gil
brain heart infusion and 5 gil yeast extract) containing 5
flglml chloramphenicol, which was then incubated at 37° C.
50 with shaking at 300 rpm overnight. About 2 ml of overnight
inoculum was added to each of four conical flasks contain-
ing 100 ml of sterilized BHY medium. The inoculated media
were then incubated at 37° C. with shaking at 300 rpm.
When the OD600 reached 3.5-4.0, the bacterial cultures were
55 heated in a water bath at 51 ° C. for 5 min and then incubated
at 37° C. with shaking at 300 rpm for a further 6 h. The
supernatant of the bacterial cultures was collected by cen-
trifugation (9000 rpm) at 4° C. for 25 min, and adjusted to
pH 7.0 with conc. HCI. The ~-Iactamaseswere extracted by
60 mixing the supernatant with 40 g of celite 545 for 30 min in
an ice bath. After discarding the supernatant, the celite was
washed three to four times with 300 ml of deionized water.
The ~-Iactamaseswere collected by mixing the celite three
times with 100 ml of protein elution buffer (100 mM
65 Tris-HCI, 2 M NaCI and 100 mM tri-sodium citrate, pH 7.0).
The protein solution was filtered by suction and then con-
centrated to 10 ml at 4° C. using a concentrator (Amicon)
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where v is the initial rate of substrate hydrolysis, Vmax the
maximum rate of reaction, [S] the initial substrate concen-
tration, Km the Michaelis constant and keat=Vma)[Enzyme].
The measured steady-state kinetic parameters for
hydrolysis ofpenicillin G, penicillin V and ampicillin by the
wild-type ~-Iactamase I, El66C and El66Cf mutants are
summarized in Table 1. The results indicate that the hydro-
lytic activity of the labeled enzyme is conserved after
labeling with fluorescein.
TABLE 1
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Fluorescence Measurements of the El66Cf Enzyme in the
Presence of Penicillins and Cephalosporins
Fluorescence measurements of the El66Cf enzyme in the
presence of penicillin G, penicillin V, ampicillin,
cefuroxime, cefoxitin and moxalactam were performed on a
Perkin Elmer LS50B spectrofluorometer. For time-resolved
fluorescence measurement, excitation and emission wave-
lengths were set at 494 and 515 nm respectively. Both
excitation and emission slit widths were set at 5 nm. All
fluorescence measurements were performed at room tem-
perature.
With penicillin G as substrate, the fluorescence signal of
the El66Cf enzyme (1.2xlO-7 M) at 515 nm in 50 mM
phosphate buffer (pH 7.0) increases as a function of the
antibiotic concentration (FIG. 4). The time-resolved fluo-
rescence signals of the El66Cf enzyme at 515 nm were also
measured with various concentrations of penicillin G (FIG.
5). At low antibiotic concentration (1.0xlO-7 and 1.0xlO-6
M), the fluorescence intensity of the El66Cf enzyme
increases gradually and then declines. At high antibiotic
concentration (1.0xlO-5 and 1.0xlO-4 M), the fluorescence
signal increases instantaneously and levels off to a plateau.
The fluorescence signal stays at the plateau for a certain
length of time and then declines afterwards. Similar results
were obtained with penicillin V and ampicillin (FIGS. 6 and
7).
With cefuroxime, cefoxitin and moxalactam as substrates,
the fluorescence intensities of the El66Cf enzyme (1.2xlO-7
M) at 515 nm in 50 mM phosphate buffer (pH 7.0) also
increase as a function of antibiotic concentration (FIGS. 8 to
10). The El66Cf enzyme exhibited increasing fluorescence
signals with antibiotic concentration, but no subsequent
65 decline in intensity was observed even after one hour.
As the fluorescence intensity of fluorescein is known to
change with pH, investigations were also made to see if the
Kw(llM)
Wild-type E166C E166Cf
15
Penicillin G 48 ± 3 72 ± 3 213 ± 11
Penicillin V 52 ± 4 71 ± 6 117±1O
Ampicillin 142 ± 8 306 ± 30 262 ± 31
1<,,", (S-1)
20
Wild-type E166C E166Cf
Penicillin G 2612 ± 320 2.07 ± 0.02 5.28 ± 0.09
Penicillin V 2109 ± 4 1.53 ± 0.03 2.97 ± 0.06
Ampicillin 5213 ± 275 4.1 ± 0.1 6.2 ± 0.2
25 kc"/K= (flM - 1S- 1)
Wild-type E166C E166Cf
Penicillin G 54 ± 10 0.029 ± 0.002 0.025 ± 0.002
Penicillin V 41 ± 4 0.021 ± 0.002 0.025 ± 0.003
30 Ampicillin 37 ± 4 0.013 ± 0.002 0.023 ± 0.004
(1)Vm~'[S]
V=---
Km + [S]
Protein Labeling
About 2.5 mg ofEl66C mutant was dissolved in 4 ml of
6 M guanidine hydrochloride. The protein solution was 10
incubated at room temperature for 30 min to unfold the
mutant. A ten-fold molar excess of fluorescein-5-maleimide
(purchased from Molecular Probes) dissolved in dimethyl-
sulfoxide was added to the protein solution, and the pH of
the mixture was adjusted to 7.5 with 0.2 M NaOH. The
mixture was stirred at room temperature for 2 h in dark, and
then dialyzed with a dialysis tubing (MWCO=12,000)
against 1 L of 20 mM NH4 HC03 (pH 7.0) at 4a C. for about
3 days to remove the free dyes. Buffer exchanges were
carried out regularly during dialysis. After dialysis, the
labeled mutant (EI66Cf) was freeze-dried and stored at _800
C.
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equipped with a piece ofYM-l membrane (MWCO=I,OOO).
The concentrated protein solution was exchanged with 20
mM NH4 HC03 and then freeze-dried. The enzyme powder
was stored at _800 C. About 15 mg ofwild-type ~-lactamase
I and 20 mg of El66C mutant were obtained by the above
procedures.
Characterization of the El66Cf Enzyme
The labeling of the El66C mutant with fluorescein-5-
maleimide was monitored by electrospray ionization mass
spectrometry (ESI/MS). The mass spectrometric measure-
ments were performed on a VG Platform mass spectrometer
(Micromass) equipped with an electrospray interface. Pro-
tein samples (20 fll) were injected into the electrospray
source via a loop injector as solution in H2 0/CH3 CN (1:1)
containing formic acid (0.2%, v/v). The mass difference
between the El66C and El66Cf mutants (FIG. 2) is con-
sistent with the molecular mass of fluorescein-5-maleimide
(MW=427) plus the mass of a sodium ion. The mass 35
spectrum of the El66Cf enzyme indicate that almost all the
El66C mutants were labeled with fluorescein molecules.
The secondary structure of the wild-type ~-lactamase I,
El66C and El66Cfwere investigated by circular dichroism
(CD) spectropolarimetry. The CD measurements were per- 40
formed on a lasco 1810 Spectropolarimeter (lasco Co.). The
CD spectra of the wild-type ~-lactamase I, El66C and
El66Cfmutants at the same concentration (6.0xlO-6 M) in
50 mM phosphate buffer (pH 7.0) on the far-UV region are
shown in FIG. 3. The CD signals exhibit no significant 45
difference, indicating that the secondary structure of the
El66Cf enzyme is conserved after labeling with fluorescein.
The hydrolytic activities of the wild-type ~-lactamase I,
El66C and El66Cf mutants towards penicillin G, penicillin
V and ampicillin (Sigma) were monitored by the spectro- 50
photometric method. The spectrophotometric measurements
were performed on a Perkin Elmer Lambda Bi020 UV/Vis
spectrometer. Substrate hydrolysis was monitored at a fixed
wavelength: 235 nm for ampicillin, 232 nm for penicillin G
and penicillin V. The initial rate of substrate hydrolysis 55
occurring within 5 min was determined in duplicate at each
of 6 different substrate concentrations in 50 mM potassium
phosphate buffer (pH 7.0) at 200 C. The initial rates deter-
mined were then treated as described in Reference 5 to
calculate the Michaelis constants (Km ) and turnover num- 60
bers (keat) using non-linear regression analysis (equation 1):
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Detection of ~-LactamAntibiotics in Milk
Fluorescence measurements of the E166Cf enzyme in
milk in the presence of penicillin G and ampicillin were
perfonned on a FLUOstar microplate reader (BMG Labtech-
nologies) equipped with two sample injectors. Excitation
and emission filters of 485 and 520 nm respectively were
used. Milk (pasteurized and homogenized, Nestle Dairy
Farm) was purchased at a local supennarket. The labeled
enzyme was mixed with the milk sample in a 96-well
microtiter plate (Corning Costar). The antibiotics were then
added to the mixtures by the injectors. The experimental
set-up is shown in FIG. 20.
FIGS. 21 and 22 show the results from the time-resolved
fluorescence measurements ofthe labeled enzyme (1.2xlO-7
M) in untreated milk in the presence of various concentra-
tions of penicillin G and ampicillin respectively. The results
Fluorescence Measurements of the E166Cf Enzyme in the
Presence of ~-Lactamase Inhibitors
Time-resolved fluorescence measurements of the E166Cf
enzyme in the presence of sulbactam and clavulanate were
perfonned on a Perkin Elmer LS50B spectrofluorometer.
The excitation and emission wavelengths were set at 494
and 515 nm respectively. Both excitation and emission slit
widths were set at 5 nm. All fluorescence measurements
40
were performed at room temperature.
The fluorescence signals of the labeled enzyme (1.2xlO-7
M) obta\ned with sulbactam (1.0xlO-4 M) and clavulanate
(1.0xlO M) in 50 mM phosphate buffer (pH 7.0) are
45 entirely different (FIGS. 18 and 19). For sulbactam, the
fluorescence intensity increases rapidly at the initial stage
and then declines slowly. For clavulanate, the addition of
substrate causes an instantaneous increase in fluorescence
signal which declines rapidly within 200 s and then levels off
50 to a plateau. These results indicate that the E166Cf enzyme
can be used to detect ~-lactamase inhibitors.
state for a while, and hence the fluorescence signal is leveled
off to a plateau (FIG. 13). This can be verified by the fact that
the 'plateau time' (8 and 22 min for 1.0xlO-5 and 1.0xlO-4
M penicillin G respectively) is consistent with the 'substrate
hydrolysis time' detennined by spectrophotometric assays
(7 and 20 min for 1.0xlO-5 and 1.0xlO-4 M penicillin G
respectively). When most of the penicillin substrates have
been hydrolyzed to carboxylic acids, the fluorescence signal
of the labeled enzyme will decline subsequently.
The absence of a declining fluorescence signal for
cefuroxime, cefoxitin and moxalactam can be ascribed to the
poor hydrolytic activities of the E166Cf enzyme towards
these antibiotics (very low k2 and/or k3 ) (FIG. 14). As a
result, the cephalosporin substrates stay in the active sites.
15 To verifY this, the activities of the labeled enzyme with
cefuroxime, cefoxitin and moxalactam as substrates were
monitored by circular dichroism (CD) spectropolarimetry.
The principle of this assay is that ~-lactam antibiotics, due
to the asymmetric property of their fused ring systems,
20 exhibit strong CD signals, but will become CD inactive
when they are hydrolyzed by ~-lactamase. Therefore, by
measuring the CD signals of cefuroxime, cefoxitin and
moxalactam (1.0xlO-4 M) at 258, 264 and 265 nm respec-
tively as a function of time in the presence of E166Cf
25 enzyme (l.2x10-7 M), the hydrolytic activities ofthe labeled
enzyme towards these antibiotics can be monitored. As
shown in FIGS. 15 to 17, no significant changes in the CD
signals appear after incubating the E166Cfenzymes with the
cephalosporin antibiotics for one hour. This indicates that
30 cefuroxime, cefoxitin and moxalactam are resistant to the
hydrolytic activity of the labeled enzyme.
E + PES*ESE + S
observed fluorescence changes were a result of the change in
pH upon hydrolysis of the antibiotics by the labeled enzyme.
First ofall, the fluorescence intensity of fluorescein is known
to decrease when the pH is lowered. So the observed
increase in fluorescence intensity in the presence of antibi-
otics is not consistent with the generation ofcarboxylic acids
upon hydrolysis by the enzyme. After the completion of
hydrolysis, the overall change in pH of the bulk phosphate
buffer solution as monitored by a pH electrode was less than
0.5 pH unit for penicillin G (1.0xlO-5 M). When the fluo- 10
rescence intensity of free fluorescein (1.2xlO-7 M) in 50
mM phosphate buffer (pH 7.0) was measured with penicillin
G, penicillin V, ampicillin, cefuroxime, cefoxitin and moxa-
lactam (1.0xlO-5 M) in the presence of unlabeled E166C
enzyme (1.2xlO-7 M), it remains almost unchanged
throughout the whole experiment (FIG. 11) while the E166C
enzyme was hydrolyzing the penicillin antibiotics (data not
shown). Moreover, cephalosporins, which are known to be
poor substrates for the E166C enzyme, also enhance the
fluorescence signals. So the possibility that the increase in
fluorescence signal of the E166Cf enzyme is due to the
change in pH of the bulk solution can be eliminated.
Furthennore, the possibility that the observed change in
fluorescence signal is due to a change in local pH at the
enzyme's active site can also be eliminated because it is
unlikely that such a change in pH at the active site takes
hundreds to thousands of seconds as shown in the time-
resolved fluorescence measurements.
Without any binding theory, the observed fluorescence
signals is believed to be attributed to the confonnational
change in the active site upon substrate binding. Upon
binding to antibiotics, the fluorescein label attached to the
flexible Q-loop may move away from the catalytic pocket
such that it is well separated from the quenchers (amino
acids) in the active site. As a result, the fluorescence of the 35
fluorescein molecule is restored.
The time-resolved fluorescence signals of the E166Cf
enzyme obtained in the presence of penicillin and cepha-
losporin antibiotics at various concentrations can be ratio-
nalized by the following three-step model:
where E is the free ~-lactamase enzyme, S the ~-lactam
substrate, ES a noncovalent enzyme-substrate complex, ES*
an acyl-enzyme complex and P the carboxylic acid.
At low substrate concentration (1.0xlO-7 and 1.0xlO-6
M), the binding between the E166Cf enzyme (E) and
penicillin substrate (S) would lead to the fonnation ofthe ES
complex and hence the enhancement in the fluorescence
signal. As hydrolysis of antibiotic proceeds, the majority of 55
the penicillin substrates are converted to free carboxylic
acids (P). As a result, most of the E166Cf enzymes return to
their substrate-free conformation (E) and hence their origi-
nal weak fluorescence signals were restored (FIG. 12). This
may explain the slow decline in fluorescence signal with 60
time after the peak.
At high substrate concentration (1.0xlO-5 and 1.0xlO-4
M), the penicillin substrates rapidly occupy the active sites
to form the ES complexes, thus switching on the fluores-
cence of the fluorescein labels instantaneously. Because the 65
antibiotic concentration is high, the continuous hydrolysis of
antibiotics would maintain the E166Cf enzymes in the ES*
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55 Penicillin G
Penicillin V
Ampicillin
Cefuroxime + +
Cefoxitin + + + +
Moxalactarn + + + +
60
E. coli
TEM-l
B. licheniformis
penP
B. cereus
penPC
TABLE 2
13-Lactamase
B. cereus 13-
lactamase II
The results indicate that cefoxitin and moxalactam are
resistant to the hydrolytic activities of the bacterial ~-Iacta­
mases, and therefore can be used in the clinical treatment if
patients are infected with bacteria which produce such
~-Iactamases.
- Decline in fluorescence signal (presence of beta-lactam hydrolysis)
+ No decline in fluorescence signal (absence of beta-lactam hydrolysis)
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Preparation of B. subtilis IA304 (<jJ105MU33I) and E. coli.
BL21(DE3) Cultures
Both B. subtilis IA304 (<jJ105MU331) and E. coli. BL21
(DE3) cultures (which produce no ~-Iactamase) were pre-
pared as negative controls for drug screening experiments.
Preparations ofB. subtilis IA304 (<jJ105MU33I) and E. coli.
BL21(DE3) cultures were performed as follows.
For B. subtilis IA304 (<jJ105MU33 I), a bacterial strain
was streaked on an agar plate containing 5 flglml chloram-
10 phenicol, and the plate was incubated at 37° C. for 24 h. A
single bacterial colony was inoculated into 100 ml of
sterilized BHY medium (37 gil brain heart infusion and 5 gil
yeast extract) which was then incubated at 37° C. with
shaking at 300 rpm overnight. After overnight incubation,
15 the bacterial culture was harvested and stored at _20° C. For
E. coli. BL21(DE3), a bacterial strain was streaked on an
agar plate containing 100 flg/ml ampicillin, and the plate was
incubated at 37° C. for 24 h. A single bacterial colony was
inoculated into 100 ml of sterilized LB broth (28 gil) which
20 was then incubated at 37° C. with shaking at 280 rpm
overnight. After overnight incubation, the bacterial culture
was harvested and stored at _20° C.
Drug Screening Experiments
Fluorescence measurements of the EI66Cf enzyme in the
presence of bacterial cultures and ~-Iactam antibiotics were
performed on a FLUOstar microplate reader (BMG Labtech-
nologies) equipped with two sample injectors. Excitation
and emission filters of 485 and 520 nm respectively were
used. For B. cereus penPC ~-Iactamase, B. licheniformis
30 penP ~-Iactamase and B. cereus ~-Iactamase II, the labeled
enzymes were mixed with the bacterial cultures, and the
mixtures were made up to 300 fll with 50 mM phosphate
buffer (pH 7.0) in a 96-well microtiter plate (Corning
Costar). For the purpose of comparison, B. subtilis cultures,
35
which produced no ~-Iactamase, were set up as negative
controls. For E. coli. TEM-I ~-Iactamase, the labeled
enzymes were mixed with the bacterial cultures without
dilution. E. coli. cultures, which produced no ~-Iactamase,
were set up as negative controls for comparison. The anti-
40 biotics were then added to the bacterial samples by the
injectors. The experimental set-up is shown in FIG. 20.
The results from the time-resolved fluorescence measure-
ments of the labeled enzyme (l.2xlO-7 M) in the presence
of various bacterial cultures and ~-Iactam antibiotics (l.Ox
45 10-4 M) are shown in FIGS. 23 to 26. Table 2 summarizes
the results obtained from the time-resolved fluorescence
measurements.
Preparation of Bacterial ~-Iactamase
Bacterial ~-Iactamases used in the drug screening experi-
ments were B. cereus penPC ~-Iactamase, B. licheniformis
penP ~-Iactamase,E. coli. TEM-I ~-IactamaseandB. cereus
~ -Iactamase II.
The ~-Iactamase II, penPC ~-Iactamase and penP ~-Iac­
tamase were expressed in B. subtilis IA304 (<jJ105MU331).
These enzymes were prepared according to the procedures
described previously (Reference 7: Thomwell, S. J. East, A.
K., Errington, J. An efficient expression and secretion sys-
tem based on Bacillus subtilis phage phi 105 and its uses for
the production for B. cereus ~-Iactamase I. (1993) Gene 133,
47-53) with slight modifications. A bacterial strain was
streaked on an agar plate containing 5 flg/ml chlorampheni-
col, and the plate was incubated at 37° C. for 24 h. A single
bacterial colony from the agar plate was inoculated into 100
ml of sterilized BHY medium (37 gil brain heart infusion
and 5 gil yeast extract) which was then incubated at 37° C.
with shaking at 300 rpm overnight. About 7 ml of overnight 50
inoculum was added to a baffled conical flask containing 100
ml of sterilized BHY medium. The inoculated medium was
incubated at 37° C. with shaking at 300 rpm. When the
optical density of the bacterial culture at 600 nm reached 3.5
to 4.0, the bacterial culture was heated in a water bath at 51 °
C. for 5 min. Afterwards, the bacterial culture was incubated
at 37° C. with shaking at 300 rpm for a further 6 h. The
bacterial culture was then harvested and stored at _20° C.
The TEM-I ~-Iactamasewas expressed in E. coli. BL21
(DE3). Preparation of the TEM-I ~-Iactamase was per-
formed as follows. A bacterial strain was streaked on an agar
plate containing 100 flg/ml ampicillin, and the plate was
incubated at 37° C. for 24 h. A single bacterial colony from
the plate was inoculated into 100 ml of sterilized LB broth
(28 gil) which was then incubated at 37° C. with shaking at 65
280 rpm overnight. After overnight incubation, the bacterial
culture was harvested and stored at _20° C.
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indicate that the labeled enzyme is capable of detecting
penicillin G and ampicillin down to 10-6 M. Therefore, the
labeled enzyme may find its application in the routine
measurement of antibiotics in liquid samples (e.g. milk).
Application of the EI66Cf Enzyme in Screening Bacteria
for ~-Lactamases against a Panel of ~-LactamAntibiotics
The use of the EI66Cf enzyme in screening bacterial
~-Iactamasesagainst various ~-Iactam antibiotics was inves-
tigated. The principle of our method is that when both
E166Cfand bacterial ~-Iactamase are incubated with '~-Iac­
tamase-unstable' antibiotics, the fluorescence of the EI66Cf
enzyme will be suppressed because of the greater catalytic
efficiency of the bacterial enzyme. In contrast, when bacte-
rial ~-Iactamases are screened against '~-Iactamase-resis­
tant' antibiotics, the fluorescence of the EI66Cfenzyme will
be enhanced because of the poor hydrolytic activity of the
bacterial enzyme. Thus, any ~-Iactam antibiotic that causes
the labeled enzyme to increase its fluorescence intensity in
the presence of bacterial ~-Iactamases can be used in clinical
treatments.
In this invention, B. cereus penPC ~-Iactamase,B. licheni-
formis penP ~-Iactamase,E. coli. TEM-I ~-IactamaseandB.
cereus ~-Iactamase II. were tested. B. cereus ~-Iactamase II 25
is classified as Class B ~-Iactamase whereas the others are
classified as Class A ~-Iactamase. Thus, we are interested to
investigate whether the labeled enzyme can be used in
screening different classes of ~-Iactamase against various
~-Iactam antibiotics.
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AlaIn, lle173, Pro174, Gly175, Asp176, llel77,
Arg178, and Lys234 replaced by an amino acid selected
from the group consisting of an amino acid containing
a free thiol group, an amino acid containing a free
carboxylic acid group, and an amino acid containing a
free amine group, and the replacing amino acid is
covalently bonded to a fluorescent indicator for gener-
ating a change of fluorescence upon binding ~-Iactam
antibiotics or ~-Iactamase inhibitors,
(2) exposing the sample to said modified ~-Iactamase
comprising a fluorescent indicator molecule, and
(3) comparing the fluorescence emitted by the modified
~-Iactamase bound with said ~-Iactam antibiotics or
~-Iactamase inhibitors, with the fluorescence emitted
by the ~-Iactamase from a control sample having no
~-Iactam antibiotics or ~-Iactamase inhibitor,
whereby the presence of ~-Iactam antibiotics or ~-Iacta­
mase inhibitors in a sample is detected.
20 2. The method as claimed in claim 1, wherein the replac-
ing amino acid is cysteine.
3. The method as claimed in claim 1, wherein the indi-
cator molecule is a fluorophore.
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While the preferred embodiment of the present invention
has been described in detail by the examples, it is apparent
that modifications and adaptations of the present invention
will occur to those skilled in the art. Furthermore, the
embodiments of the present invention shall not be inter-
preted to be restricted by the examples or figures only. It is
to be expressly understood, however, that such modifica-
tions and adaptations are within the scope of the present
invention, as set forth in the following claims. For instance,
features illustrated or described as part of one embodiment 10
can be used on another embodiment to yield a still further
embodiment. Thus, it is intended that the present invention
cover such modifications and variations as come within the
scope of the claims and their equivalents.
The invention claimed is:
1. A method for detecting ~-Iactam antibiotics or ~-Iac­
tamase inhibitors in a sample, comprising the steps of:
(I) providing a modified ~-Iactamase for binding with
said ~-Iactam antibiotics or ~-Iactamase inhibitors,
wherein the modified ~-Iactamase is a wild-type ~-Iac­
tamase having a residue at a position that corresponds
to a position in the amino acid sequence of the Bacillus
cereus ~-Iactamase I selected from the group consisting
of Ser70, Lys73 , Asp104, Serl30, Asn163, Arg164,
Phe165, Thr167, Glu168, Leu169, Asn170, Glu171,
